Polarean Imaging PLC System installation (5782O)
October 11 2021 - 2:00AM
UK Regulatory
TIDMPOLX
RNS Number : 5782O
Polarean Imaging PLC
11 October 2021
11 October 2021
Polarean Imaging Plc
("Polarean" or the "Company")
System Installation
Polarean Imaging plc (AIM: POLX), the medical - imaging
technology company, with an investigational drug - device
combination product for magnetic resonance imaging (MRI), announces
the installation of its 9820 Xenon Polariser system at BC
Children's Hospital, Vancouver BC, a major paediatric research and
teaching hospital.
The hyperpolarisation system order was previously announced in
May 2021, with the system being used to support BC Children's
Hospital's research into paediatric pulmonary disease.
Richard Hullihen, Chief Executive Officer of Polarean commented:
"We are pleased to complete the installation of an investigational
9820 Xenon Polariser system at BC Children's Hospital. We look
forward to its use in research to expand the knowledge base in
pulmonary disease areas."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Jonathan Allis, Non-Executive Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams / Fred Walsh (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879 741
001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, investigational
drug-device combination companies operating in the high-resolution
medical imaging research space.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation. (129) Xe gas is currently
being studied for visualisation of gas exchange regionally in the
smallest airways of the lungs, across the alveolar tissue barrier,
and into the pulmonary bloodstream.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel investigational
diagnostic approach, offering a non-invasive and radiation-free
functional imaging platform. The annual economic burden of
pulmonary disease in the US is estimated to be over US$150
billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEANEEFSXFFFA
(END) Dow Jones Newswires
October 11, 2021 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024